Especially critical amid the continuing global pandemic, key metrics are laid out to help life sciences companies define, measure, and effectively communicate sustainability practices and progress—and build foundations for long-term business value.
The future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.
A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.
As the world of medicine continues to face the impact of the COVID-19 pandemic, clinicians are increasingly looking to digital solutions, including continuing medical education (CME), to stay current on the latest developments in their field.
What can both public and private sector stakeholders learn from current trends to accelerate innovation around the COVID-19 pandemic and other emerging global health threats, including antimicrobial resistance?
Emerging technologies like digital twins offer supply chain efficiency solutions, allowing the industry to integrate sustainable practices while ensuring patient safety.
There has been a push to implement NFTs, or non-fungible tokens, across many verticals, but there is still much to learn about their potential uses in healthcare and its brands.
Using the interview process to ensure high organizational standards.
A look at the intersection of rigorous compliance and ethical behavior: independent, charitable patient assistance foundations.
Dual-targeted injection poised to rock GLP-1 field in diabetes—and eventually weight loss.
Patient protection and social influence among trends to look out for as calendar turns.
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Virtual audits proving to be beneficial post-COVID despite continuing challenges.
Industry veteran Ken Abreu makes the case for approaching market access very early in the process, and elucidates why it's so important.
Social Media is omnipresent and harnessing its power should be high on lists of healthcare providers (HCPs). How do they get their message out to reach the right people at the right time and how do they distinguish themselves from their competitors? Here are 12 predictions and factors for 2022.
How early stage can help set you up for big stage.
Life sciences companies a likely targets of these kinds of attacks.
Webinar Date/Time: Mon, Dec 5, 2022 2:00 PM EST
Leveraging RWD can lessen the strain normally put on investigators and sites.
How technology can maximize use of manufacturer copay and patient assistance programs.
Five emerging themes likely to impact pharma in the new year.
Dr. Chris Smyth, president of ICON Biotech, discusses emerging trends in the biotech space.
This application note summarizes key SIFT-MS results presented in a peer reviewed article entitled “Unreported VOC Emissions from Road Transport Including from Electric Vehicles.” Learn how the Wolfson Atmospheric Chemistry Laboratory at the University of York used SIFT-MS for VOC analysis in its platform to experimentally verify that motor vehicle screen wash is a significant unreported source of VOC emissions (especially for ethanol and methanol).
Oral solid dose formulations (OSD) continue to lead the market as a preferred dosage form. To gain better insight into drug dose delivery technology trends, Laura Child spoke to leaders from five top contract development and manufacturing organizations to find out what is on the horizon for patient-centric drug delivery.
New regulations set stage for updated ESG considerations.
Insight that can help smaller biotech companies prepare for commercialization in the world of big pharma.
Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.